SCHEMBL3617442

SCHEMBL3617442

C=CCC(N)(C(=O)OCC)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
ALDH1A1 P00352 4/20 0.49
TSHR P16473 3/20 0.49
PIN1 Q13526 1/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.40
MMP8 P22894 1/20 0.40
POLB P06746 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP3A4 P08684 1/20 0.39
MAPT P10636 3/20 0.39
THRB P10828 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3617440 1.00 HTT (0.50) HTTALDH1A1TSHRPIN1KMT2A
SCHEMBL8353354 0.87 CA12 (0.42) HTTALDH1A1TSHRKMT2AMEN1
SCHEMBL2987235 0.84 HTT (0.53) HTTALDH1A1TSHRKMT2AMEN1
SCHEMBL1455681 0.84 PIN1 (0.50) ALDH1A1TSHRPIN1KMT2AMEN1
SCHEMBL10951249 0.83 ALDH1A1 (0.50) HTTALDH1A1TSHRPIN1KMT2A
Hydrochloric Acid SCHEMBL1977471 0.83 PIN1 (0.49) ALDH1A1TSHRPIN1KMT2AMEN1
SCHEMBL27579783 0.83 PIN1 (0.49) ALDH1A1TSHRPIN1KMT2AMEN1
SCHEMBL27315973 0.81 PIN1 (0.47) ALDH1A1TSHRPIN1KMT2AMEN1
SCHEMBL7490885 0.81 ALDH1A1 (0.51) HTTALDH1A1TSHRPIN1KMT2A
SCHEMBL31174124 0.80 RECQL (0.55) ALDH1A1PIN1SMN1; SMN2MAPK1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666862-B2 2,4-Diphenyl-1-(hexamethylenimin-4-ylaminocarbonyl)dihydropyrrole derivatives that are useful for treating cancer MERCK & CO., INC. (US) 2010-02-23 US disclosed
US-7666862-B2 2,4-Diphenyl-1-(hexamethylenimin-4-ylaminocarbonyl)dihydropyrrole derivatives that are useful for treating cancer MERCK & CO., INC. (US) 2010-02-23 US disclosed
US-7666862-B2 2,4-Diphenyl-1-(hexamethylenimin-4-ylaminocarbonyl)dihydropyrrole derivatives that are useful for treating cancer MERCK & CO., INC. (US) 2010-02-23 US disclosed
US-7638549-B2 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropyrrolidin3-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide; antiproliferative and -carcinogenic agents MERCK & CO. INC. (US) 2009-12-29 US disclosed
US-7638549-B2 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropyrrolidin3-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide; antiproliferative and -carcinogenic agents MERCK & CO. INC. (US) 2009-12-29 US disclosed
US-7638549-B2 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropyrrolidin3-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide; antiproliferative and -carcinogenic agents MERCK & CO. INC. (US) 2009-12-29 US disclosed
EP-1656146-A4 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2009-04-15 EP disclosed
EP-1664026-B1 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2009-01-21 EP disclosed
EP-1664026-B1 MITOTIC KINESIN INHIBITORS MERCK & CO INC (US) 2009-01-21 EP disclosed
US-7465746-B2 Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP MERCK & CO., INC. (US) 2008-12-16 US disclosed
US-7235580-B2 Mitotic kinesin inhibitors MERCK & CO., INC. (US) 2007-06-26 US disclosed
US-7235580-B2 Mitotic kinesin inhibitors MERCK & CO., INC. (US) 2007-06-26 US disclosed
US-20060287302-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2006-12-21 US disclosed
US-20060234984-A1 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator MERCK & CO., INC. 2006-10-19 US disclosed
WO-2006101780-A1 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2006-09-28 WO disclosed
EP-1656146-A2 MITOTIC KINESIN INHIBITORS Merck & Co., Inc. (US) 2006-05-17 EP disclosed
US-20060100191-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2006-05-11 US disclosed
WO-2005018547-A2 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2005-03-03 WO disclosed
US-20050043357-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2005-02-24 US disclosed
US-20050038074-A1 Mitotic kinesin inhibitors COLEMAN PAUL J (US) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060234984-A1 Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator KIF5B, KIF2C, KIF5C HTT 3197/4885ALDH1A1 1044/4885TSHR 3477/4885
US-20050043357-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIF18B HTT 986/4885ALDH1A1 2302/4885TSHR 4772/4885
US-20060100191-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIF18B HTT 986/4885ALDH1A1 2302/4885TSHR 4772/4885
US-20060287302-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIF18B HTT 986/4885ALDH1A1 2302/4885TSHR 4772/4885
US-20050038074-A1 Mitotic kinesin inhibitors KIF5B, KIF2C, KIF18B HTT 986/4885ALDH1A1 2302/4885TSHR 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.